Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL29599595 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29588704 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3343160 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30361066 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29566149 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL34378 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL53998 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30465862 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL5504285 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300904-A1 | PYRIDAZINONES FOR THE TREATMENT OR PREVENTION OF HYPERTENSION | UNIVERSITETET I OSLO (NO) | 2024-09-12 | — | — | US | claimed |
| EP-4351518-A1 | PYRIDAZINONES FOR THE TREATMENT OR PREVENTION OF HYPERTENSION | Universitetet I Oslo (NO) | 2024-04-17 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| WO-2022258992-A1 | PYRIDAZINONES FOR THE TREATMENT OR PREVENTION OF HYPERTENSION | UNIVERSITETET I OSLO (NO) | 2022-12-15 | — | — | WO | claimed |
| WO-2026106969-A1 | NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE | UNIVERSITY OF ROCHESTER (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4706684-A2 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | The Regents of The University of Michigan (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4034253-B1 | COMPOSITIONS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | UNIV MICHIGAN REGENTS (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250320190-A1 | Novel Inhibitors of Leucine Carboxyl Methyltransferase-1 (LCMT-1) and Methods of Use Thereof | UNIV TEMPLE (US) | 2025-10-16 | — | — | US | disclosed |
| CN-112888431-B | Dexmedetomidine-containing film preparation and method for producing the same | 比奥克斯塞尔医疗股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | UNIV NEW YORK STATE RES FOUND (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220133637-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311538-B2 | Compositions and methods for targeting cancers | YALE UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11304911-B2 | Compositions and methods for organ specific delivery of nucleic acids | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3980005-A1 | CARABACHOL-BROMONIDINE FORMULATION TO ENHANCE ANTI-PRESBYOPIA EFFECTS | Visus Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022036290-A1 | PHARMACEUTICAL COMPOSITION CONTAINING COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022020661-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 | THE UNIVERSITY OF ROCHESTER (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | ADRA1A 1947/4885ADRA1D 2093/4885ADRA1B 1056/4885 |
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | ADRA1A 1547/4885ADRA1D 1810/4885ADRA1B 1422/4885 |
| US-20240300904-A1 | PYRIDAZINONES FOR THE TREATMENT OR PREVENTION OF HYPERTENSION | REN, AGTR1, AGTR2 | ADRA1A 9/4885ADRA1D 10/4885ADRA1B 22/4885 |
| US-20220133637-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | ADRA1A 2676/4885ADRA1D 3816/4885ADRA1B 2921/4885 |
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | ACE, SARS1, ACE2 | ADRA1A 4353/4885ADRA1D 4484/4885ADRA1B 4459/4885 |
| US-11304911-B2 | Compositions and methods for organ specific delivery of nucleic acids | POLRMT, FABP1, SNRPE | ADRA1A 2676/4885ADRA1D 3816/4885ADRA1B 2921/4885 |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | FABP1, POLRMT, LIPC | ADRA1A 3144/4885ADRA1D 4045/4885ADRA1B 3487/4885 |
| US-20250320190-A1 | Novel Inhibitors of Leucine Carboxyl Methyltransferase-1 (LCMT-1) and Methods of Use Thereof | GNMT, BHMT, SHMT1 | ADRA1A 4085/4885ADRA1D 4054/4885ADRA1B 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.